EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma

Imran A Nizamuddin, Armin Ghobadi iD

American Society of Clinical Oncology Educational Book · 2025

DOI: 10.1200/edbk-25-473302 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025. Verfasst von Imran A Nizamuddin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Washington University in St Louis School of Medicine, Saint Louis, MO. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), have revolutionized the treatment of various B-cell non-Hodgkin lymphomas. A number of agents are now approved by regulatory agencies for treatment of large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, and more agents are currently under review. Notably, while the current approvals are for single agents in the relapsed/refractory setting, clinical trials are now investigating combination approaches as well as incorporating cellular therapies and BsAbs into earlier lines of treatment. This article focuses on cellular therapies and BsAbs for treatment of various lymphomas, including review of completed or ongoing trials of using these platforms in earlier lines which have the potential to be practice changing in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificLymphoma, Mantle-CellLymphoma, FollicularReceptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseImmunotherapy, AdoptiveHumans

Substanzen

Antibodies, BispecificReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Washington University in St Louis School of Medicine, Saint Louis, MO.

ORCID-Profile: Armin Ghobadi

Zitieren

APA

Nizamuddin, I. A., & Ghobadi, A. (2025). Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-25-473302

Vancouver

Nizamuddin IA, Ghobadi A. Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma. American Society of Clinical Oncology Educational Book. 2025. doi:10.1200/edbk-25-473302

BibTeX
@article{Nizamuddin2025,
  author = {Nizamuddin, Imran A and Ghobadi, Armin},
  title = {Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2025},
  doi = {10.1200/edbk-25-473302}
}
Kostenlos starten →